Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: A case study on human and bovine proteasomes

BMC Genomics

Volumn 11, Issue SUPPL. 4, 2010, Pages

  Grover, Abhinav ^a   Shandilya, Ashutosh ^a   Bisaria, Virendra S ^a   Sundar, Durai ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

20S PROTEASOME; PROTEASOME; UNCLASSIFIED DRUG; WITHAFERIN A; ANTINEOPLASTIC AGENT; LIGAND; PLANT MEDICINAL PRODUCT; WITHANOLIDE;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME STABILITY; MAMMAL; MATHEMATICAL ANALYSIS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; ANIMAL; APOPTOSIS; BIOLOGY; CATTLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROTEIN BINDING; SIGNAL TRANSDUCTION;

BOS TAURUS; BOVINAE; EUKARYOTA; HOMO SAPIENS; MAMMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATTLE; COMPUTATIONAL BIOLOGY; HUMANS; LIGANDS; MODELS, MOLECULAR; PLANT PREPARATIONS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; SIGNAL TRANSDUCTION; WITHANOLIDES;

ANTI-CANCER MECHANISM; ANTITUMOR DRUGS; BINDING MODES; BOS TAURUS; CELLULAR EVENTS; CELLULAR PROCESS; CELLULAR PROLIFERATIONS; CYTOSOLS; DISEASE TREATMENT; EPOXYKETONES; EUKARYOTIC CELLS; HERBAL DRUG; HIGH RATE; HOMO SAPIENS; HYDROXYL GROUPS; IMMUNOGENICITY; INFLAMMATORY RESPONSE; INHIBITION MECHANISMS; MODE OF ACTION; MOLECULAR DOCKING; MOLECULAR DYNAMICS SIMULATIONS; N-TERMINALS; NATURAL PRODUCTS; NONPEPTIDE; NUCLEAR FACTORS; ORAL ADMINISTRATION; PROTEASOME INHIBITORS; PROTEASOMES; PROTEOLYTIC ACTIVITIES; PROTEOLYTIC SYSTEM; REGULATORY PROTEIN; RESEARCH TOOLS; STRUCTURAL STABILITIES; SYNTHETIC CHEMICALS; TIME-PERIODS; TOXIC SIDE EFFECTS; TRANSCRIPTIONAL FACTORS; UBIQUITIN; VINYL SULFONES; WORK SUPPORT; X RAY CRYSTAL STRUCTURES;

ALDEHYDES; AMINO ACIDS; BINDING ENERGY; CELL DEATH; CELL PROLIFERATION; CHEMICAL COMPOUNDS; CRYSTAL STRUCTURE; DISEASES; LIGANDS; MAMMALS; MOLECULAR DYNAMICS; MOLECULAR MODELING; PATHOLOGY; PEPTIDES; SIGNAL TRANSDUCTION; STABILITY; TRANSCRIPTION FACTORS;

BIOINFORMATICS;

EID: 78649781036     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-11-S4-S15     Document Type: Article

References (53)

1. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of 20S proteasome from yeast at 2.4 angstrom resolution. Nature 1997, 386(6624):463-471. 10.1038/386463a0, 9087403.
2. Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, Tsukihara T. The structure of the mammalian 20S proteasome at 2.75 angstrom resolution. Structure 2002, 10(5):609-618. 10.1016/S0969-2126(02)00748-7, 12015144.
3. Peters JM. Proteasomes - Protein-Degradation Machines of the Cell. Trends Biochem Sci 1994, 19(9):377-382. 10.1016/0968-0004(94)90115-5, 7985232.
4. Voges D, Zwickl P, Baumeister W. The 26S proteasome: A molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999, 68:1015-1068. 10.1146/annurev.biochem.68.1.1015, 10872471.
5. Peters JM, Franke WW, Kleinschmidt JA. Distinct 19-S and 20-S Subcomplexes of the 26-S Proteasome and Their Distribution in the Nucleus and the Cytoplasm. J Biol Chem 1994, 269(10):7709-7718.
6. Groll M, Heinemeyer W, Jager S, Ullrich T, Bochtler M, Wolf DH, Huber R. The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study. P Natl Acad Sci USA 1999, 96(20):10976-10983.
7. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem 1997, 272(40):25200-25209. 10.1074/jbc.272.40.25200, 9312134.
8. Nussbaum AK, Dick TP, Keilholz W, Schirle M, Stevanovic S, Dietz K, Heinemeyer W, Groll M, Wolf DH, Huber R, et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. P Natl Acad Sci USA 1998, 95(21):12504-12509.
9. Brannigan JA, Dodson G, Duggleby HJ, Moody PCE, Smith JL, Tomchick DR, Murzin AG. A Protein Catalytic Framework with an N-Terminal Nucleophile Is Capable of Self-Activation. Nature 1995, 378(6555):416-419. 10.1038/378416a0, 7477383.
10. Chen P, Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 1996, 86(6):961-972. 10.1016/S0092-8674(00)80171-3, 8808631.
11. Schmidtke G, Kraft R, Kostka S, Henklein P, Frommel C, Lowe J, Huber R, Kloetzel PM, Schmidt M. Analysis of mammalian 20S proteasome biogenesis: The maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis. Embo J 1996, 15(24):6887-6898. 452515, 9003765.
12. Seemuller E, Lupas A, Baumeister W. Autocatalytic processing of the 20S proteasome. Nature 1996, 382(6590):468-470. 10.1038/382468a0, 8684489.
13. Lupas A, Zwickl P, Wenzel T, Seemuller E, Baumeister W. Structure and function of the 20S proteasome and of its regulatory complexes. Cold Spring Harb Sym 1995, 60:515-524.
14. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998, 67:425-479. 10.1146/annurev.biochem.67.1.425, 9759494.
15. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001, 21(4):245-273. 10.1002/med.1009, 2556558, 11410931.
16. Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 2007, 107(3):687-717. 10.1021/cr0502504, 17316053.
17. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5(5):417-421. 10.1016/S1535-6108(04)00120-5, 15144949.
18. Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006, 5(7):1836-1843. 10.1158/1535-7163.MCT-06-0066, 16891470.
19. Colson K, Doss DS, Swift R, Tariman J, Thomas TE. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs 2004, 8(5):473-480. 10.1188/04.CJON.473-480, 15515281.
20. Alhindawi MK, Alkhafaji SH, Abdulnabi MH. Antigranuloma Activity of Iraqi Withania-Somnifera. J Ethnopharmacol 1992, 37(2):113-116. 10.1016/0378-8741(92)90069-4, 1434685.
21. Mishra L, Singh B, Dagenias S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 2000, 5:334-336.
22. Owais M, Sharad KS, Shehbaz A, Saleemuddin M. Antibacterial efficacy of Withania somnifera (ashwagandha) an indigenous medicinal plant against experimental murine salmonellosis. Phytomedicine 2005, 12(3):229-235. 10.1016/j.phymed.2003.07.012, 15830846.
23. Bhattacharya A, Ghosal S, Bhattacharya SK. Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J Ethnopharmacol 2001, 7(4):1-6.
24. Kulkarni SK, George B, Mathur R. Protective effect of Withania somnifera root extract on electrographic activity in a lithium-pilocarpine model of status epilepticus. Phytotherapy Research 1998, 12(6):451-453.
25. Kulkarni S, George B, Mathur R. Protective effect of Withania somnifera root extract on electrographic activity in a lithium pilocarpine model of status epilepticus. Phytother Res 1998, 12:451-453.
26. Furmanowa M, Gajdzis-Kuls D, Ruszkowska J, Czarnocki Z, Obidoska G, Sadowska A, Rani R, Upadhyay SN. In vitro propagation of Withania somnifera and isolation of withanolides with immunosuppressive activity. Planta Med 2001, 67(2):146-149. 10.1055/s-2001-11494, 11301861.
27. Kaileh M, Vanden W, Heyerick A, Horion J, Piette J, Libert C, De Keukeleire D, Essawi T, Haegeman G. Withaferin A strongly elicits I kappa B kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem 2007, 282(7):4253-4264. 10.1074/jbc.M606728200, 17150968.
28. Oh JH, Kwon TK. Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappa B in human pulmonary epithelial cells. Int Immunopharmacol 2009, 9(5):614-619. 10.1016/j.intimp.2009.02.002, 19236958.
29. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappa B (NF-kappa B) activation and NF-kappa B-regulated gene expression. Mol Cancer Ther 2006, 5(6):1434-1445. 10.1158/1535-7163.MCT-06-0096, 16818501.
30. Mohan R, Hammers H, Bargagna-Mohan P, Zhan X, Herbstritt C, Ruiz A, Zhang L, Hanson A, Conner B, Rougas J, et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004, 7(2):115-122. 10.1007/s10456-004-1026-3, 15516832.
31. Yang HJ, Shi GQ, Dou QP. The tumor proteasome is a primary target for the natural anticancer compound withaferin a isolated from "Indian Winter Cherry". Mol Pharmacol 2007, 71(2):426-437. 10.1124/mol.106.030015, 17093135.
32. Sali A, Blundell TL. Comparative Protein Modeling by Satisfaction of Spatial Restraints. J Mol Biol 1993, 234(3):779-815. 10.1006/jmbi.1993.1626, 8254673.
33. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 2000, 28(1):235-242. 10.1093/nar/28.1.235, 102472, 10592235.
34. Kleywegt GJ, Jones TA. Phi/psi-chology: Ramachandran revisited. Structure 1996, 4(12):1395-1400. 10.1016/S0969-2126(96)00147-5, 8994966.
35. NCBI-PubChem Compound database. , http://pubchem.ncbi.nlm.nih.gov/
36. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998, 19(614):1639-1662.
37. Sanner MF. Python: A programming language for software integration and development. J Mol Graph Model 1999, 17(1):57-61.
38. Bikadi Z, Hazai E. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. J Cheminform 2009, 1:15. 10.1186/1758-2946-1-15, 2820493, 20150996.
39. Gupta A, Gandhimathi A, Sharma P, Jayaram B. ParDOCK: An all atom energy based Monte Carlo docking protocol for protein-ligand complexes. Protein Peptide Lett 2007, 14(7):632-646.
40. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Crowley M, Walker RC, Zhang W, et al. AMBER 10. 2008, University of California.
41. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of Simple Potential Functions for Simulating Liquid Water. J Chem Phys 1983, 70(2):926-935.
42. Jakalian A, Bush BL, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic Charges. AM1-BCC model: I. Method. J Comput Chem 2000, 21(2):132-146.
43. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 1996, 118(9):2309-2309.
44. Berendsen HJC, Postma JPM, Vangunsteren WF, Dinola A, Haak JR. Molecular-Dynamics with Coupling to an External Bath. J Chem Phys 1984, 81(8):3684-3690.
45. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical-Integration of Cartesian Equations of Motion of a System with Constraints - Molecular-Dynamics of N-Alkanes. J Comput Phys 1977, 23(3):327-341.
46. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A Smooth Particle Mesh Ewald Method. J Chem Phys 1995, 103(19):8577-8593.
47. Kim DH, Park JI, Chung SJ, Park JD, Park NK, Han JH. Cleavage of beta-lactone ring by serine protease. Mechanistic implications. Bioorgan Med Chem 2002, 10(8):2553-2560.
48. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. Mechanistic studies on the inactivation of the proteasome by lactacystin A central role for clasto-lactacystin beta-lactone. J Biol Chem 1996, 271(13):7273-7276. 10.1074/jbc.271.13.7273, 8631740.
49. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8(6590):739-758. 10.1016/S1074-5521(01)00056-4, 11514224.
50. Laskowski RA, Macarthur MW, Moss DS, Thornton JM. Procheck - a Program to Check the Stereochemical Quality of Protein Structures. J Appl Crystallogr 1993, 26:283-291.
51. Mozzicafreddo M, Cuccioloni M, Cecarini V, Eleuteri AM, Angeletti M. Homology Modeling and Docking Analysis of the Interaction between Polyphenols and Mammalian 20S Proteasomes. J Chem Inf Model 2009, 49(2):401-409. 10.1021/ci800235m, 19434841.
52. Smith DM, Daniel KG, Wang ZG, Guida WC, Chan TH, Dou QP. Docking studies and model development of tea polyphenol proteasome inhibitors: Applications to rational drug design. Proteins 2004, 54(1):58-70. 10.1002/prot.10504, 14705024.
53. Dou QP, Landis-Piwowar KR, Chen D, Huo C, Wan SB, Chan TH. Green tea polyphenols as a natural tumour cell proteasome inhibitor. Inflammopharmacology 2008, 16(5):208-212. 10.1007/s10787-008-8017-8, 18815743.